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Summary Most drugs available for cancer chemotherapy exert their effects through cytodestruction.
Although significant advances have been attained with these cytotoxic agents in several malignant diseases,
response is often accompanied by significant morbidity and many common malignant tumours respond
poorly to existing cytotoxic therapy. Development of chemotherapeutic agents with non-cytodestructive
actions appears desirable. Considerable evidence exists which indicates that (a) the malignant state is not
irreversible and represents a disease of altered maturation, and (b) some experimental tumour systems can be
induced by chemical agents to differentiate to mature end-stage cells with no proliferative potential. Thus, it is
conceivable that therapeutic agents can be developed which convert cancer cells to benign forms. To study the
phenomenon of blocked maturation, squamous carcinoma SqCC/Yl cells were employed in culture. Using
this system it was possible to demonstrate that physiological levels of retinoic acid and epidermal growth
factor were capable of preventing the differentiation of these malignant keratinocytes into a mature tissue-like
structure. The terminal differentiation caused by certain antineoplastic agents was investigated in HL-60
promyelocytic leukaemia cells to provide information on the mechanism by which chemotherapeutic agents
induce cells to by-pass a maturation block. The anthracyclines aclacinomycin A and marcellomycin were
potent inhibitors of N-glycosidically linked glycoprotein biosynthesis and transferrin receptor activity, and
active inducers ofmaturation; temporal studies suggested that the biochemical effects were associated with the
differentiation process. 6-Thioguanine produced cytotoxicity in parental cells by forming analog nucleotide. In
hypoxanthine-guanine phosphoribosyltransferase negative HL-60 cells the 6-thiopurine initiated maturation;
this action was due to the free base (and possibly the deoxyribonucleoside), a finding which separated
termination of proliferation due to cytotoxicity from that caused by maturation.
Significant advances have been made towards the
cure and palliation of cancer with existing chemo-
therapeutic agents; however, since the mechanism
of action of these drugs is dependent upon the
cytodestruction of neoplastic cells, their beneficial
effects are usually accompanied by significant
morbidity. This suggests that approaches to cancer
therapy should be sought that do not involve cell
kill; one such approach envisions the conversion of
malignant cells through induced differentiation to
benign forms with no proliferative potential. This
approach assumes that malignancy is not an
irreversible state, as has been demonstrated with a
variety of tumour types, including teratocarcinomas
(Pierce & Wallace, 1971; Brinster, 1974), neuro-
blastomas (Schubert et al., 1971; Prasad, 1983)
squamous cell carcinomas (Pierce & Wallace, 1971),
leukaemias (Metcalf et al., 1969; Paran et al., 1970;
Gootwine et al., 1982), and adenocarcinomas of the
breast (Decosse et al., 1973; Pierce et al., 1977). The
use of differentiation as a therapeutic approach also
presumes that cancer is a disease of altered
maturation. Such a phenomenon can be readily
visualized in constantly renewing tissues in which
mature cellular elements with a finite life-span are
continually being regenerated by an active stem cell
compartment. The carcinogenic event may be
visualized to interfere with the progression of a
developing cell through the maturation pathway,
blocking that cell at a stage at which it retains
infinite proliferative capability. Under these
conditions, an amplification of the altered clone is
produced, and progression to more anaplastic
forms can occur. In tissues devoid of a stem cell
population such as neurons, it is simplest to
envision a dedifferentiation caused by the carcino-
genic event, which leads to a more primitive cellular
form with proliferative capability. Investigations of
the role of oncogenes on the blockage of
differentiation have demonstrated that in muscle
cells certain genes have a direct effect on the
expression of a developmental program, whereas
others act indirectly to disrupt the regulation of
growth, preventing withdrawal of cells from the
proliferative pool (Falcone et al., 1985). The thera-
peutic objective, in all of these situations, is to push
cells by the block in maturation so that they may
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progress to more mature cellular elements with no
proliferative capability.
Squamous cell carcinoma as a model of blocked
maturation
Evidence is available which suggests that malignant
epithelial cells have a decreased capacity to undergo
terminal differentiation relative to their normal
counterparts (Rheinwald & Beckett, 1980; Yuspa &
Morgan, 1981; Parkinson et al., 1983). Thus,
normal murine skin keratinocytes undergo a
significant degree of terminal maturation in tissue
culture when calcium is present in high concen-
trations, whereas carcinogen-treated mouse skin
cells fail to differentiate as measured by keratiniza-
tion under similar conditions (Yuspa & Morgan,
1981). Furthermore, transformed human keratino-
cytes exhibit a decreased capacity to attain a
differentiated state when treated with phorbol-12-
myristate 13-acetate (Parkinson et al., 1983). In an
analogous manner, human squamous carcinoma
cells of the skin or the head and neck region
differentiated much more slowly than normal
epithelial cells when artificially deprived of
anchorage (Rheinwald & Beckett, 1980).
Elucidation of the mechanisms that regulate the
differentiation of malignant epithelial cells
compared to their normal counterparts would
appear to be important for the development of
effective therapeutic approaches that employ
differentiation as the strategic tactic in these
diseases.
We have used a human cell line (SqCC/Yl)
derived from a carcinoma of the stratified
squamous epithelium of the cheek as a model to
study the regulation of the differentiation of
malignant keratinocytes (Reiss et al., 1985; 1985
submitted). These cells grow predominantly as a
monolayer in culture medium consisting of equal
volumes of Dulbecco's modified Eagle's medium
and Ham's medium F12 supplemented with 10%
heat inactivated foetal bovine serum. Replacement
of the serum supplemented medium by one
containing insulin, transferrin and selenium in place
of the foetal bovine serum, resulted in spontaneous
maturation that involved the formation of a strati-
fied structure composed of four to six layers of
cells, with a progressive thinning of the cells in
layers furthest removed from the surface of the
culture plate. Desmosomes were present and cells
became elongated and progressively devoid of
structure except for tonofilament bundles.
Keratinization occurred and the cells attained the
capacity to form a cornified cell envelope in a
manner that resembled that of the maturation of
normal epidermal cells in culture (Holbrook &
Hennings, 1983). Two factors which interfered with
the differentiation of SqCC/Yl cells in culture were
retinoic acid, at a concentration as low as 10-8 M
(Reiss et al., 1985; 1985 submitted) and epidermal
growth factor (EGF), which inhibited maturation at
a level of 0.1 ngml - (King & Sartorelli, 1985).
Both the retinoids and EGF may well function to
regulate normal epithelial cell proliferation and
differentiation since both of these agents are
capable of interfering with normal keratinocyte
maturation in culture (Sun & Green, 1976; Fuchs &
Green, 1981; Green & Watt, 1982; Cline & Rice,
1983; Kim et al., 1984; Wille et al., 1984).
Differences in the sensitivity of normal and
malignant epithelial cells to these agents may well
be involved in the blockage of maturation which
occurs in squamous cell carcinomas; thus Kim et al.
(1984) have shown that 10 times more retinyl
acetate is required to interfere with normal
keratinocyte differentiation than is required to
affect the maturation of malignant epithelial cells.
In a like manner, comparison of the findings of
Wille et al. (1984) with normal keratinocytes to our
unpublished data (King & Sartorelli 1985) with
SqCC/Yl cells suggests that the malignant cell line
may be about 10 times more sensitive to the
blockage of maturation produced by EGF than its
normal cellular counterpart. This apparent
difference in the sensitivity to the blocking action of
EGF on the maturation process may be related to
the concentration of EGF receptors on the cell
surface, since Cowley et al. (1984), using a relatively
large number of malignant epithelial cell lines, have
shown that the number of EGF receptors per cell is
3.4- to 54-fold higher in cultured malignant
keratinocytes than in normal keratinocytes.
Circumvention of the effects of the retinoid block
on SqCC/Yl cells can be obtained using hydro-
cortisone, which appears to be competitive with the
retinoids (Reiss et al., 1985a). This finding is
consistent with the reports of Rice et al. (1983) and
of Cline & Rice (1983) who have shown that
hydrocortisone increased the fraction of differen-
tiated FCC-13 squamous carcinoma cells in cultures
treated with retinyl acetate. It would appear, that
the attainment of an approach to circumvention of
the EGF blockage of differentiation of malignant
keratinocytes that might be employed in
combination with hydrocortisone could be useful in
the treatment of at least some squamous cell
carcinomas.
Terminal differentiation of HL-60 acute
promyelocytic leukaemia cells by cancer
chemotherapeutic agents
A variety of compounds, such as cryoprotective
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hormones (Lotem & Sachs, 1975), vitamins
(Breitman et al., 1980; Takenaga et al., 1980; Abe
et al., 1981; Schwartz et al., 1983a), tumour
promoters (Huberman & Callaham, 1979; Lotem &
Sachs, 1979), and several clinically useful cancer
chemotherapeutic agents (Lotem & Sachs, 1974;
Ebert et al., 1976; Gusella & Houseman, 1976;
Scher & Friend, 1978; Terada et al., 1978; Collins
et al., 1980; Papac et al., 1980; Bodner et al., 1981;
Gallo et al., 1982; Schwartz & Sartorelli, 1982;
Schwartz et al., 1983b; Ishiguro et al., 1984),
promote the differentiation of various cell types in
culture. Thus, it is conceivable that some of the
antineoplastic agents currently in use may exert
their therapeutic effects through a mixture of cyto-
destructive and differentiation-inducing actions. The
anthracyclines represent a class of cancer chemo-
therapeutic agents with significant potency as
inducers of the differentiation of HL-60 leukaemia
cells. The more conventional clinically used anthra-
cycline antibiotics such as adriamycin and dauno-
rubicin are inactive as initiators of the maturation
of this leukaemia cell line; however, the
oligosaccharide-containing anthracyclines, aclacino-
mycin A and marcellomycin, are potent inducers of
differentiation, being active in the nanomolar
region (Schwartz & Sartorelli, 1982). The activity of
these latter two agents would appear to be due to
the trisaccharide portion of the molecules, since the
corresponding monosaccharide anthracycline pyrro-
mycin was at best an exceedingly weak inducer of
maturation in this system. Examination of the
effects of dimethylsulphoxide and marcellomycin on
the growth of HL-60 cells in culture indicated that
little replication took place from 5 to 10 days after
exposure of cells to these two agents (Schwartz &
Sartorelli, 1982); these effects appeared to be due to
a mixture of cytotoxic and differentiation
producing actions by both the polar solvent and the
anthracycline.
Virtually all agents which induce the maturation
of leukaemia cells in culture express this activity at
a concentration slightly below that required to
produce cell death. It is important to emphasize
that it is exceedingly difficult to separate the
phenomenon of termination of proliferation by
differentiation from that of cell kill, since terminal
differentiation to a mature cell leads to a finite life
span. Furthermore, since these cells cannot be
expected to achieve complete normalcy, their life
span may be relatively short. That HL-60
leukaemia cells treated with anthracyclines undergo
a commitment to terminal maturation has been
demonstrated in an in vivo clonal assay by our
laboratory (Schwartz et al., 1983a). These studies
have demonstrated that HL-60 cells undergo an
average of 4 and a maximum of 5 divisions
following commitment to undergo granulocytic
differentiation when exposed to marcellomycin.
They are in agreement with findings using the
Friend erythroleukaemia which demonstrate an
inducer stimulated transition to a restriction in the
self-renewing capabilities of the cells (Gusella et al.,
1976; Osborne et al., 1982).
Aclacinomycin A would appear to be the anthra-
cycline with the most clinical potential since this
antibiotic has considerably less myelotoxicity than
its counterpart, marcellomycin, and both antibiotics
are equiactive as inducers of differentiation.
Approximately 40% of patients with previously
untreated acute leukaemia have been reported to
respond to aclacinomycin with complete remissions
(Yamada et al., 1980). Of considerable interest are
reports which indicate that the response rate in
patients refractory to chemotherapy or relapsing
after receiving drugs, including adriamycin and
daunorubicin, was 17 to 30% (Yamata et al., 1980;
DeJager et al., 1981; Warrell et al., 1981). Further-
more, Sakurai et al., (1983) reported the response
of a patient with acute myeloblastic leukaemia to
aclacinomycin A which was suggestive of a differen-
tiative process.
The anthracycline antibiotics produce a variety of
metabolic actions which may be responsible for the
initiation of maturation and the subsequent
termination of proliferation through the formation
of end-stage cells (see for a review, Young et al.,
1981). Many studies have suggested that the
anthracyclines exert their cytotoxic effects by virtue
of intercalation with DNA (see for example,
Painter, 1978). DuVernay et al. (1979) reported that
the length of the oligosaccharide side-chain of the
anthracycline was a major determinant in the
binding of these agents to DNA. This group also
demonstrated that the oligosaccharide-containing
anthracyclines, such as marcellomycin and
aclacinomycin A, inhibit RNA synthesis in vitro at
concentrations which are from 6- to 19-fold lower
than those required to inhibit DNA biosynthesis
(DuVernay et al., 1978). In contrast, the mono-
saccharide-containing anthracyclines, adriamycin,
daunorubicin and pyrromycin, inhibit the synthesis
of both RNA and DNA at essentially equivalent
concentrations. A clear difference exists between the
activities of marcellomycin and aclacinomycin and
those of adriamycin and pyrromycin with respect to
the inhibition of nucleolar RNA synthesis relative
to that of DNA synthesis (Crooke et al., 1978).
Furthermore, the former compounds were markedly
more potent in terms of the inhibition of nucleolar
RNA synthesis than were the latter anthracyclines.
Thus, it is conceivable that the capacity to inhibit
nucleolar RNA synthesis is related to the ability of
marcellomycin and aclacinomycin to act as potent
inducers of HL-60 cell differentiation, while the
ineffectiveness of adriamycin and pyrromycin as296 A.C. SARTORELLI
initiators of maturation may be due to their
relatively poor potency as inhibitors of RNA
synthesis.
We have observed that aclacinomycin A and
marcellomycin are potent inhibitors of both total
glycoprotein synthesis and the formation of lipid-
linked oligosaccharide intermediates in intact HL-
60 cells, while adriamycin and pyrromycin are
inactive (Morin & Sartorelli, 1984). This inhibitory
activity by aclacinomycin and marcellomycin was
both concentration and time dependent and
occurred under conditions in which both cellular
growth and total protein synthesis were maintained
at levels equal to those of untreated cells. In
contrast, exposure of HL-60 cells to pyrromycin or
adriamycin, even at cytotoxic concentrations, did
not result in a selective decrease in the synthesis of
glycoproteins containing asparagine-linked oligo-
saccharides. These findings demonstrated a new
biochemical site of action for aclacinomycin and
marcellomycin and suggested that this activity was
involved in the induction of the terminal differen-
tiation of HL-60 leukaemia cells by these anti-
tumour agents. Evidence is available to suggest that
perturbations in glycoprotein biosynthesis may be
important to the commitment of neoplastic cells to
enter a differentiation pathway. Thus, Nakayasu et
al. (1980) have reported that the exposure of HL-60
leukaemia cells to tunicamycin, an inhibitor of N-
glycosidically-linked glycoprotein biosynthesis
(Heifetz et al., 1979), led to the production of
phenotypically mature cells. Retinoic acid, which
also has the potential to interfere with the
formation of lipid-linked oligosaccharide inter-
mediates (Creek et al., 1983), is also a potent
inducer of HL-60 leukaemia cell maturation
(Collins et al., 1980). In addition, a number of
investigators (Cossu et al., 1982; Felsted et al.,
1983; Skubitz & August, 1983) have demonstrated
changes in the expression of cell surface glyco-
proteins during the induction of differentiation of
leukaemia cells. Among the best characterized of
these modifications are changes in the expression of
the transferrin receptor (TFR), the down regulation
of which appears to be involved in the series of
programmed events that lead to the termination of
proliferation through differentiation to mature
cellular forms. Thus, when a variety of leukaemia
systems (i.e., M-1, K562, or HL-60 cells) are
induced to differentiate to more functionally mature
cells by a variety of agents, including dexa-
methasone, dimethylsulphoxide, butyrate, or
retinoic acid, the cell surface expression of the
transferrin receptor is significantly reduced as an
early event (Schulman et al., 1981; Tei et al., 1982;
Testa et al., 1982; Trowbridge et al., 1982; Yeh et
al., 1982; Felsted et al., 1983; Morin & Sartorelli,
1984). Furthermore, anti-TFR monoclonal
antibodies inhibit the growth of a variety of
malignant cell lines (Trowbridge et al., 1982; Taetle
et al., 1983; 1985). Exposure of HL-60 cells to the
anthracyline inducers of differentiation aclacino-
mycin and marcellomycin produced a pronounced
decrease in the level of cell surface TFR (Morin &
Sartorelli, 1984). In contrast, Testa et al. (1982)
have shown that TFR activity was not lost in non-
inducible leukaemic cell lines exposed to cytotoxic
concentrations of inducers such as sodium butyrate.
In addition, adriamycin and pyrromycin, which do
not induce the differentiation of HL-60 cells, do not
decrease the level of TFR (Morin & Sartorelli,
1984). Omary & Trowbridge (1981) have demon-
strated the importance of the carbohydrate moieties
of the TFR protein to its function in human
leukaemic cells. Thus, under conditions in which
the glycosylation of TFR is compromised by the
presence of an inhibitor of glycoprotein bio-
synthesis, the overall expression of the TFR in the
binding of transferrin to the surface of cells is
decreased. The mechanism by which the down
regulation of the TFR functions as part of a series
of programmed events involved in the termination
of cellular proliferation caused by inducers of
differentiation may well involve the obligatory role
of iron in the catalytic action of the enzyme ribo-
nucleoside diphosphate reductase, which is critical
for the synthesis of DNA, and constitutes a
sensitive regulatory site because of the relatively
small pools of deoxyribonucleoside triphosphates
present in cells. In addition, the necessity of iron
for the generation of ATP by the cytochromes
would impact on the deficiency in the deoxyribo-
nucleotide building blocks of DNA produced by
the decrease in ribonucleoside diphosphate
reductase activity.
Separation of mechanisms involved in the termination
of proliferation by differentiation from those caused
by cytotoxicity through the use of 6-thioguanine
The inducers of maturation have chemical
structures and biological activities that are so
diverse that no unifiable concept on the underlying
mechanism of induction has been reached. Among
metabolic inhibitors, several antimetabolites such as
3-deazauridine, pyrazofurin (Bodner et al., 1981),
tiazofurin and mycophenolic acid (Lucas et al.,
1983a; 1983b; Sokoloski & Sartorelli, 1984), and
xylosyladenine (Garret & Kredich, 1981) have been
reported to be effective inducers of the
differentiation of the Friend erythroleukaemia and
the HL-60 promyelocytic leukaemia. The optimum
concentrations of these analogues for the induction
of maturation are in the range where they elicitMALIGNANT CELL DIFFERENTIATION 297
cytotoxicity, suggesting that the mechanisms
responsible for both processes are identical. This
concept is supported by the finding that xylosy-
ladenine (Garret & Kredich, 1981) and bromo-
deoxyuridine (Koeffler et al., 1983) are devoid of
inducing ability in mutant cell lines with deletions
in adenosine kinase and thymidine kinase,
respectively. Furthermore, induction of the
erythroid differentiation of Friend cells by the
aminonucleoside puromycin is inhibited by inosine
(Terada et al., 1978), an antagonist of this analogue
nucleoside (Studzinski & Ellem, 1968). These results
collectively support the concept that the activation
of these analogues to the nucleotide level not only
is essential for cytotoxicity but is also required for
the induction of maturation.
6-Thioguanine differs from these agents in that it
is an effective initiator of maturation in both
Friend and HL-60 leukaemia cells deficient in
hypoxanthine-guanine phosphoribosyl transferase
(HGPRT) (Gusella & Houseman, 1976; Schwartz et
al., 1982; Gallagher et al., 1984; Ishiguro et al.,
1984) but at best is only weakly active against
parental wild type cells (Papac et al., 1980;
Gallagher et al., 1984; Ishiguro et al., 1984).
Considerable evidence is available to support the
concept that 6-thioguanine, like most purines and
pyrimidines and their nucleosides, must be
converted to the nucleotide level to express
cytotoxicity (see for example, Brockman, 1963).
Multiple sites of action have been described for
thioguanine nucleotides, including their incor-
poration into both RNA and DNA (Sartorelli et
al., 1958; LePage, 1960; LePage & Jones, 1961;
LePage & Howard, 1963; Bieber & Sartorelli, 1964;
Kwan et al., 1973; Carrico & Sartorelli, 1977), and
inhibition of glutamine phosphoribosylpyrophos-
phate amidotransferase (McCollister et al., 1964;
Hill & Bennett, 1969), inosine 5'-phosphate
dehydrogenase (Hampton, 1963; Miech et al.,
1967), adenosine triphosphate: guanosine 5'-
phosphate phosphotransferase (Miech et al., 1969)
and glycoprotein biosynthesis (Lazo et al., 1977;
1979). To identify the metabolic form(s) of 6-
thioguanine responsible for the induction of the
differentiation of HL-60/HGPRT- cells, intra-
cellular and extracelklar metabolites of thioguanine
were analyzed (Ishiguro et al., 1984). The purine
antimetabolite was not appreciably metabolized by
these cells, indicating that 6-thioguanine itself was
the metabolic form which initiated maturation. The
capacity of 6-thioguanosine and 3 -2'-deoxythiog-
uanosine to induce differentiation was also
examined. When HL-60/HGPRT- cells were
incubated with these nucleosides, large amounts of
the nucleosides were converted to 6-thioguanine by
purine nucleoside phosphorylase (PNP); the
simultaneous exposure of the cells to 6-
thioguanosine or fl-2'-deoxythioguanosine and 8-
aminoguanosine, an inhibitor of PNP activity,
minimized degradation of the nucleosides. Under
these conditions, intracellular accumulation of
thioguanine nucleotides occurred, presumably
through the action of nucleoside kinase activities,
and no induction of differentiation was observed.
Deoxycytidine kinase (DCK) has been shown to
phosphorylate fl-2'-deoxythioguanosine (Nakai &
LePage, 1972). To eliminate the action of DCK, a
double mutant of HL-60 cells deficient in both
HGPRT and DCK activities was developed. In
these cells, ,B-2'-deoxythioguanosine was devoid of
cytotoxicity and was an effective inducer of
maturation. The potency of deoxythioguanosine as
an inducer in this sytem was not prevented by the
presence of 8-aminoguanosine, suggesting that
deoxythioguanosine itself was also an active
initiator of maturation. The findings also suggested
that the formation of 6-thioguanine nucleotides
serves to antagonize the maturation process in
addition to producing cytotoxicity. Furthermore,
the studies demonstrate that the metabolic form(s)
of the purine antimetabolite which induce differen-
tiation differ from those that produce cytotoxicity,
implying that the biochemical events required to
arrest growth by these different processes are
distinct. In support of this conclusion, differences
occurred in the stage of cell cycle arrest produced
by 6-thioguanine in parental and HL-60/HGPRT-
cells (Schwartz et al., 1985). Wild type HL-60 cells
treated with the purine antimetabolite accumulated
in the S and G2 +M phases of the cell cycle, a
finding similar to that occurring in other cell lines
demonstrating toxicity when treated with this agent
(Wotring & Roti Roti, 1980). In contrast, HL-
60/HGPRT- cells which terminate proliferation
through maturation when treated with 6-
thioguanine accumulated in Gi. Arrest of cells in
G1 is not unexpected for mature cells (see for
example, Prescott, 1976). In support of this
concept, both HL-60 and HL-60/HGPRT- cells
respond to dimethylsulphoxide by the initiation of
differentiation and an increase in G cells.
Parental HL-60 cells respond to the exposure to
6-thioguanine with cytotoxicity rather than differen-
tiation; this action is due to the fact that the
concentration of the purine antimetabolite required
to induce maturation in this cell line is significantly
higher than that required to produce cytotoxicity.
Toxicity of 6-thioguanine to parental cells could be
circumvented by exposing thioguanine treated HL-
60 cells simultaneously to hypoxanthine or its
nucleosides (Ishiguro & Sartorelli, 1985). Under
these conditions, accumulation of 6-thioguanine
nucleotides, the cytotoxic form(s) of this agent in
HL-60 cells treated with the purine antimetabolite,
was markedly decreased by the presence of the298 A.C. SARTORELLI
physiological purine. This resulted in a marked
decrease in the cytotoxic potency of thioguanine,
and the differentiation inducing properties of the
purine antimetabolite were expressed. Hypox-
anthine protects against the cytodestructive
properties of thioguanine by preventing the
anabolism of the purinethiol to its nucleotide level;
this may occur through competition between
hypoxanthine and 6-thioguanine at several levels.
These include (a) the transport carrier for hypox-
anthine/guanine (Plagemann et al., 1981); (b) the
enzyme HGPRT; and (c) 5-phosphoribosyl 1-pyro-
phosphate (PRPP), with the activation of hypox-
anthine to inosine 5'-phosphate leading to a
decreased availability of PRPP for the synthesis of
6-thioguanosine 5'-phosphate by HGPRT.
Information of this kind would appear to be critical
before an agent such as 6-thioguanine is tested for
its capacity to induce maturation in a clinical
setting.
Conclusions
A few trials have been conducted to determinc
whether the induction of leukaemia cell differcn-
tiation could be attained in a clinical setting (see for-
appropriate references, Schwartz & Wiernik, 1985).
These investigations suffer from an inability to
differentiate between the cytotoxic and maturation
producing actions of the agents employed. In
addition, considerable additional fundamental
information would appear to be required to most
efficaciously apply the concepts of differentiation
therapy to the treatment of malignant diseases of
man. Phenomena such as commitment time, which
often requires one to two cell generations of
continuous exposure in culture to inducing agent to
achieve an irreversible commitment to form end-
stage mature cells, suggests that continuous
infusion of agents under test would be required for
this period of time for optimum effects in patients
with malignant disease. This possible requirement is
sorely in need of evaluation in an animal system.
The phenomenon of memory, whereby cells
exposed to an inducer of differentiation for less
than the period of time required to achieve
commitment retain this information for an
additional division cycle or more, and undergo a
significant degree of differentiation when cells are
reexposed to inducer for a relatively short period of
time consistent with an appropriate cumulative
exposure to that inducer (see for example, Fibach et
al., 1979; Murate et al., 1984; Yen et al., 1984; Yen,
1984) is a potentially important phenomenon to
clinical usage of agents of this kind. We have found
that precommitment to memory initiated by a
priming dose of one agent can be imparted to
different inducing agents, making it possible to
employ the clinical concept of spreading drug
toxicity over several organ systems, while affecting
the total neoplastic cell population. Since tumour
cell heterogeneity would be expected to limit the
effectiveness of a single inducer of differentiation it
will be important to seek combinations of agents
that act in a synergistic manner in the same cells, as
well as on different portions of the cell population,
to initiate maturation. Furthermore, since it is
probable that all cells in a malignant cell
population will not have the capacity to respond to
inducers of maturation to generate end-stage cells
with no proliferative capacity, it is also critical to
seek mixtures of agents that would function
through both differentiation and cytotoxic actions
without mutual antagonism. Differentiation therapy
as an approach can be envisioned to yield major
decreases in the neoplastic cell burden without the
degree of morbidity produced by aggressive therapy
with cytodestructive agents used in combination.
Effective introduction of differentiating agents into
cancer therapy if attained will be an important
addition to our therapeutic armamentarium.
The research from the author's laboratory described in
this report was supported in part by US Public Health
Service Grants CA-02817, CA-28852, and CA-08341 from
the National Cancer Institute.
References
ABE, E., MIYAURA, C., SAKAGAMI, H. & 5 others (1981).
Differentiation of mouse myeloid leukemia cells
induced by la,25-dihydroxyvitamin D3. Proc. Natl
Acad. Sci., 78, 4990.
BIEBER, A.L. & SARTORELLI, A.C. (1964). The
metabolism of thioguanine in purine analog-resistant
cells. Cancer Res., 24, 1210.
BODNER, A.J., TING, R.C. & GALLO, R.C. (1981).
Induction of differentiation of human promyelocytic
leukemia cells (HL-60) by nucleosides and
methotrexate. J. Natl Cancer Inst., 67, 1025.
BREITMAN, T.R., SELONICK, S.E. & COLLINS, S.J. (1980).
Induction of differentiation of the human
promyelocytic leukemia cell line (HL-60) by retinoic
acid. Proc. Nall. Acad. Sci., 77, 2936.
BRINSTER, R.L. (1974). The effects of cells transferred
into the mouse blastocyst on subsequent development.
J. Exp. Med., 140, 1049.
BROCKMAN, R.W. (1963). Mechanisms of resistance to
anticancer agents. Adv. Cancer Res., 7, 129.MALIGNANT CELL DIFFERENTIATION 299
CARRICO, C.K. & SARTORELLI, A.C. (1977). Effect of 6-
thioguanine on RNA biosynthesis in regenerating liver.
Cancer Res., 37, 1876.
CLINE, P.R. & RICE, R.H. (1983). Modulation of
involucrin and envelope competence in human
keratinocytes by hydrocortisone, retinyl acetate, and
growth arrest. Cancer Res., 43, 3203.
COLLINS, S.J., BODNER, A., TING, R. & GALLO, R.C.
(1980). Induction of morphological and functional
differentiation of human promyelocytic leukemia cells
(HL-60) by compounds which induce differentiation of
murine leukemia cells. Int. J. Cancer, 25, 213.
COSSU, G., KUO, A.L., PESSANO, S., WARREN, L. &
COOPER, R.A. (1982). Decreased synthesis of high
molecular weight glycopeptides in human
promyelocytic leukemia cells (HL-60) during phorbol
ester-induced macrophage differentiation. Cancer Res.,
42, 484.
COWLEY, G., SMITH, J.A., GUSTERSON, B., HENDLER, F.
& OZANNE, B. (1984). The amount of EGF receptors
is elevated on squamous cell carcinomas. In Cancer
Cells 1. The Transformed Phenotype. (Eds. Levine et
al.) p. 5. Cold Spring Harbor: New York.
CREEK, K.E., MORRE, J.D., SILVERMAN-JONES, C.S.,
SHIDOJI, Y. & DELUCA, L.M. (1983). Mannosyl carrier
functions of retinyl phosphate and dolichyl phosphate
in rat liver endoplasmic reticulum. Biochem. J., 210,
541.
CROOKE, S.T., DuVERNAY, V.H., GALVAN, L. &
PRESTAYKO, A.W. (1978). Structure-activity
relationships of anthracyclines relative to effects on
macromolecular syntheses. Mol. Pharmacol., 14, 290.
DECOSSE, J.J., GOSSENS, C.L., KUZMA, J.F. &
UNSWORTH, B.R. (1973). Breast cancer: Induction of
differentiation by embryonic tissue. Science, 181, 1057.
DEJAGER, R., DELGADO, M., BAYSSAS, M. & 5 others
(1981). Phase II study of aclacinomycin in acute
leukemia and leukemic lymphosarcoma. Proc. Am.
Assoc. Cancer Res., 22, 171 (Abstract).
DuVERNAY, V.H., ESSERY, J.M., DOYLE, T.W., BRADNER,
W.T. & CROOKE, S.T. (1979a). The antitumor effects of
anthracyclines. The importance of the carbomethoxy-
group at position-10 of marcellomycin and
rudolfomycin. Mol. Pharmacol., 15, 341.
DuVERNAY, V.H., PACHTER, J.A. & CROOKE, S.T.
(1979b). Deoxyribonucleic acid binding studies on
several new anthracycline antitumor antibiotics.
Sequence preference and structure-activity
relationships of marcellomycin and its analogues as
compared to adriamycin. Biochemsitry, 18, 4024.
EBERT, P.S., WARS, I. & BUELL, D.N. (1976). Erythroid
differentiation in cultured Friend leukemia cells treated
with metabolic inhibitors. Cancer Res., 36, 1809.
FALCONE, G., TATO, F. & ALEMX, S. (1985). Distinctive
effects of the viral oncogenes myc, erb, fps, and src on
the differentiation program of quail myogenic cells.
Proc. Natl Acad. Sci., 82, 426.
FELSTED, R.L., GUPTA, S.K., GLOVER, C.J., FISCHKOFF,
S.A. & GALLAGHER, R.E. (1983). Cell surface
membrane protein changes during the differentiation
of cultured human promyelocytic leukemia. HL-60
cells. Cancer Res., 43, 2754.
FIBACH, E., GAMBERI, R., SHAW, P.A. & 5 others (1979).
Tumor promoter-mediated inhibition of cell
differentiation: Suppression of the expression of
erythroid functions in murine erythroleukemia cells.
Proc. Natl Acad. Sci., 76, 1906.
FRIEND, C., SCHER, W., HOLLAND, J.G. & SATO, T.
(1971). Hemoglobin synthesis in murine virus-induced
leukemia cells in vitro: Stimulation of erythroid
differentiation by dimethyl sulfoxide. Proc. Natl Acad.
Sci., 68, 378.
FUCHS, E. & GREEN, H. (1981). Regulation of terminal
differentiation of cultured human keratinocytes by
vitamin A. Cell, 25, 617.
GALLAGHER, R.E., FERRARI, A.C., ZULICH, A.W., YEN,
R-W.-C. & TESTA, J.R. (1984). Cytotoxic and cyto-
differentiative components of 6-thioguanine resistance
in HL-60 cells containing acquired double minute
chromosomes. Cancer Res., 44, 2642.
GALLO, R.C., BREITMAN, T.R. & RUSCETTI, F.W. (1982).
Proliferation and differentiation of human myeloid
leukemia cell lines in vitro. In: Maturation Factors and
Cancer (Ed. Moore), p. 255. Raven Press, New York.
GARRET, C. & KREDICH, N.M. (1981). Induction of
hemoglobin synthesis by xylosyladenine in murine
erytholeukemia cells. Metabolism of xylosyladenine
and effects on transmethylation. J. Biol. Chem., 256,
12705.
GOOTWINE, E., WEBB, C. & SACHS, L. (1982).
Participation of myeloid leukemic cells injected into
embryos on hematopoietic differentiation in adult
mice. Nature, 299, 63.
GREEN, H. & WATT, F.M. (1982). Regulation by vitamin
A of envelope cross-linking in cultured keratinocytes
derived from different human epithelia. Mol. Cell.
Biol., 2, 1115.
GUSELLA, J., GELLER, R., CLARKE, B., WEEKS, V. &
HOUSEMAN, D. (1976). Commitment to erythroid
differentiation by Fried erythroleukemia cells: A
stochastic analysis. Cell, 9, 221.
GUSELLA, J.F. & HOUSEMAN, D. (1976). Induction of
erythroid differentiation in vitro by purines and purine
analogues. Cell, 8, 263.
HAMPTON, A. (1963). Reactions of ribonucleotide
derivatives of purine analogues at the catalytic site of
inosine 5'-phosphate dehydrogenase. J. Biol. Chem.,
238, 3068.
HEIFETZ, A., KEENAN, R.W. & ELBEIN, A.D. (1979).
Mechanism of action of tunicamycin on the UDP-
glcNAc: Dolichylphosphate glcNAc-l-phosphate
transferase. Biochemistry, 8, 2186.
HILL, D.L. & BENNETT, L.L., Jr. (1969). Purification and
properties of 5-phosphoribosylpyrophosphate amido-
transferase from adenocarcinoma 755 cells.
Biochemistry, 8, 122.
HOLBROOK, K.A. & HENNINGS, H. (1983). Phenotypic
expression of epidermal cells in vitro: A review. J.
Invest. Derm., 81, 1Is.
HUBERMAN, E. & CALLAHAM, M.F. (1979). Induction of
terminal differentiation in human promyelocytic
leukemia cells by tumor-promoting agents. Proc. Natl
Acad. Sci., 76, 1293.300 A.C. SARTORELLI
ISHIGURO, K. & SARTORELLI, A.C. (1985). Enhancement
of the differentiation-inducing properties of 6-
thioguanine by hypoxanthine and its nucleosides in
HL-60 promyelocytic leukemia cells. Cancer Res., 45,
91.
ISHIGURO, K., SCHWARTZ, E.L. & SARTORELLI, A.C.
(1984). Characterization of the metabolic forms of 6-
thioguanine responsible for cytotoxicity and induction
of differentiation of HL-60 acute promyelocytic
leukemia cells. J. Cell Physiol., 121, 383.
KIM, K.H., SCHWARTZ, F. & FUCHS, E. (1984).
Differences in keratin synthesis between normal
epithelial cells and squamous cell carcinomas are
mediated by vitamin A. Proc. Natl Acad. Sci., 81,
4280.
KING, C.L. & SARTORELLI, A.C. (1985). Oncogene
expression and the role of epidermal growth factor
receptor (EGFR) in the terminal differentiation of
cultured human malignant keratinocytes (SqCC/Y1).
Proc. Am. Assoc. Cancer Res., 26, 40 (Abstract).
KOEFFLER, H.P., YEN, J. & CARLSON, J. (1983). The
study of human myeloid differentiation using
bromodeoxyuridine (BrdU). J. Cell. Physiol., 116, 111.
KWAN, S.-W., KWAN, S.-.P. & MANDEL, H.G. (1973). The
incorporation of 6-thioguanine into RNA fraction and
its effect on RNA and protein biosynthesis in mouse
sarcoma 180 ascites cells. Cancer Res., 33, 950.
LAZO, J.S., HWANG, K.M. & SARTORELLI, A.C. (1977).
Inhibition of L-fucose incorporation into glycoprotein
of sarcoma 180 cells by 6-thioguanine. Cancer Res., 37,
4250.
LAZO, J.S., SHANSKY, C.W. & SARTORELLI, A.C. (1979).
Reduction in cell surface concanavalin A binding and
mannose incorporation into glycoproteins of sarcoma
180 by 6-thioguanine. Biochem. Pharmacol., 28, 583.
LEPAGE, G.A. (1960). Incorporation of 6-thioguanine into
nucleic acids. Cancer Res., 20, 403.
LEPAGE, G.A. & HOWARD, N. (1963). Chemotherapy
studies on mammary tumors of C3H mice. Cancer
Res., 23, 622.
LEPAGE, G.A. & JONES, M. (1961). Further studies on
mechanism of action of 6-thioguanine. Cancer Res.,
21, 1590.
LOTEM, J. & SACHS, L. (1974). Different blocks in the
differentiation of myeloid leukemic cells. Proc. Natl
Acad. Sci., 71, 3507.
LOTEM, J. & SACHS, L. (1975). Induction of specific
changes in the surface membrane of myeloid leukemic
cells by steroid hormones. Int. J. Cancer, 15, 731.
LOTEM, J. & SACHS, L. (1979). Regulation of normal
differentiation in mouse and human myeloid leukemia
cells by phorbol esters and the mechanism of tumor
promotion. Proc. Natl Acad. Sci., 76, 5158.
LUCAS, D.L., ROBINS, R.K., KNIGHT, R.D. & WRIGHT,
D.G. (1983a). Induced maturation of the human pro-
myelocytic leukemia cell line, HL-60, by 2-,B-D-ribo-
furanosylselenazole-4-carboxamide. Biochem. Biophys.
Res. Commun., 115, 971.
LUCAS, D.L., WEBSTER, H.K. & WRIGHT, D.G. (1983b).
Purine metabolism in myeloid precursor cells during
maturation. Studies with the HL-60 cell line. J. Clin.
Invest., 72, 1889.
McCOLLISTER, R.J., GILBERT, W.R., Jr., ASHTON, D.W. &
WYNGAARDEN, J.B. (1964). Pseudofeedback inhibition
of purine synthesis by 6-mercaptopurine ribonucleotide
and other purine analogues. J. Biol. Chem., 239, 1560.
METCALF, D., MOORE, M.A.S. & WARNER, N.L. (1969).
Colony formation in vitro by myelomonocytic
leukemic cells. J. Nati Cancer Inst., 43, 983.
MIECH, R.P., PARKS, R.E., Jr., ANDERSON, J.H., Jr. &
SARTORELLI, A.C. (1967). An hypothesis on the
mechanism of action of 6-thioguanine. Biochem.
Pharmacol., 16, 2222.
MIECH, R.P., YORK, R. & PARKS, R.E., Jr. (1969).
Adenosine triphosphate-guanosine 5'-phosphate
phosphotransferase. II. Inhibition by 6-thioguanosine
5'-phosphate of the enzyme isolated from hog brain
and sarcoma 180 ascites cells. Mol. Pharmacol., 5, 30.
MORIN, M.J. & SARTORELLI, A.C. (1984). Inhibition of
glycoprotein biosynthesis by the inducers of HL-60 cell
differentiation, aclacinomycin A and marcellomycin.
Cancer Res., 44, 2807.
MURATE, T., KANEDA, T., RIFKIND, R.A. & MARKS, P.A.
(1984). Inducer-mediated commitment of murine
erythroleukemia cells to terminal cell division: The
expression of commitment. Proc. Natl Acad. Sci., 81,
3394.
NAKAI, Y. & LEPAGE, G.A. (1972). Characterization of the
kinase(s) involved in the phosphorylation of x- and ,B-
2'-deoxythioguanosine. Cancer Res., 32, 2445.
NAKAYASU, M., TERDA, M., TAMURA, G. & SUGIMURA,
T. (1980). Induction of differentiation of human and
murine myeloid leukemia cells in culture by
tunicamycin. Proc. Natl Acad. Sci., 77, 409.
OMARY, M.B. & TROWBRIDGE, I.S. (1981). Biosynthesis
of the human transferrin receptor in cultured cells. J.
Biol. Chem., 256, 12888.
OSBORNE, H.B., BAKKE, A.C. & YU, J. (1982). Effect of
dexamethasone on hexamethylene bisacetamide-
induced Friend cell erythrodifferentiation. Cancer Res.,
42, 513.
PAINTER, R.B. (1978). Inhibition of DNA replicon
initiation by 4-nitroquinoline 1-oxide, adriamycin, and
ethyleneimine. Cancer Res., 38, 4445.
PAPAC, R.J., BROWN, A.E., SCHWARTZ, E.L. &
SARTORELLI, A.C. (1980). Differentiation of human
promyelocytic leukemia cells in vitro by 6-thioguanine.
Cancer Lett., 10, 33.
PARAN, M., SACHS, L., BARAK, Y. & RESNITZKY, P.
(1970). In vitro induction of granulocytic differen-
tiation in hematopoietic cells from leukemic and non-
leukemic patients. Proc. Natl Acad. Sci., 67, 1542.
PARKINSON, E.K., GRABHAM, P. & EMMERSON, A.
(1983). A subpopulation of cultured keratinocytes
which is resistant to the induction of terminal
differentiation-related changes by phorbol, 12-
myristate, 13-acetate: Evidence for an increase in the
resistant population following transformation.
Carcinogenesis, 4, 857.
PIERCE, G.B., NAKANE, P.K., MARTINEZ-HERMANDEZ,
A. & WARD, J.M. (1977). Ultrastructural comparison of
differentiation of stem cells of murine adeno-
carcinomas of colon and breast with their normal
counterparts. J. Natl Cancer Inst., 58, 1329.MALIGNANT CELL DIFFERENTIATION 301
PIERCE, G.B. & WALLACE, C. (1971). Differentiation of
malignant to benign cells. Cancer Res., 31, 127.
PLAGEMANN, P.G.W., MARZ, R., WOHLHUETER, R.M.,
GRAFF, J.C. & ZYLKA, J.M. (1981). Facilitated
transport of 6-mercaptopurine and 6-thioguanine and
non-mediated permeation of 8-azaguanine in Novikoff
rat hepatoma cells and relationship to intracellular
phosphorylation. Biochim. Biophys. Acta, 647, 49.
PRASAD, K.N. (1983). Therapeutic potentials of
differentiating agents in neuroblastomas. Prog. Clin.
Biol. Res., 132C, 75.
PRESCOTT, D.M. (1976). Cell cycle and control of cellular
reproduction. Adv. Genet., 18, 99.
REISS, M., PITMAN, S.W. & SARTORELLI, A.C. (1985).
Modulation of the terminal differentiation of human
squamous carcinoma cells in vitro by all-trans retinoic
acid. J. Natl Cancer Inst., 74, 1015.
REUBEN, R.C., RIFKIN, R.A. & MARKS, P.A. (1980).
Chemically induced murine erythroleukemia
differentiation. Biochim. Biophys. Acta, 605, 325.
RHEINWALD, J.G. & BECKETT, M.A. (1980). Defective
terminal differentiation in culture as a consistent and
selectable character of malignant human keratinocytes.
Cell, 22, 629.
RICE, R.H., CLINE, P.R. & COE, E.L. (1983). Mutually
antagonistic effects of hydrocortisone and retinyl
acetate on envelope competence in cultured malignant
human keratinocytes. J. Invest. Derm., 81, 176s.
SAKURAI, M., SAMPI, K. & HOZUMI, H. (1983). Possible
differentiation of human acute myeloblastic leukemia
cells by daily and intermittent administration of
aclacinomycin A. Leuk. Res., 7, 139.
SARTORELLI, A.C., LEPAGE, G.A. & MOORE, E.C. (1958).
Metabolic effects of 6-thioguanine. I. Studies on
thioguanine-resistant and -sensitive Ehrlich ascites
cells. Cancer Res., 18, 1232.
SCHER, W. & FRIEND, C. (1978). Breakage of DNA and
alteration in folded genomes by inducers of
differentiation in Friend erythroleukemia cells. Cancer
Res., 38, 841.
SCHUBERT, D., HUMPHREYS, S., JACOB, F. & DEVITRY,
F. (1971). Induced differentiation of a neuroblastoma.
Dev. Biol., 25, 514.
SCHULMAN, H.M., WILCZYNSKA, A. & PONKA, P. (1981).
Transferrin and iron uptake by human lymphoblastoid
and K-562 cells. Biochem. Biophys. Res. Commun.,
100, 1523.
SCHWARTZ, E.L., BROWN, B.J., NIERENBURG, M.,
MARSH, J.C. & SARTORELLI, A.C. (1983a). Evaluation
of some anthracycline antibiotics in an in vivo model
for studying drug-induced human leukemia cell
differentiation. Cancer Res., 43, 2725.
SCHWARTZ, E.L., ISHIGURO, K. & SARTORELLI, A.C.
(1983b). Induction of leukemia cell differentiation by
chemotherapeutic agents. Adv. Enz. Reg., 21, 3.
SCHWARTZ, E.L. & SARTORELLI, A.C. (1982). Structure-
activity relationships for the induction of
differentiation of HL-60 human acute leukemia cells
by anthracyclines. Cancer Res., 42, 2651.
SCHWARTZ, E.L., SNODDY, J.R., KREUTTER, D.,
RASMUSSEN, H. & SARTORELLI, A.C. (1983c).
Synergistic induction of HL-60 differentiation by 1,25-
dihydroxyvitamin D3 and dimethyl sulfoxide (DMSO).
Proc. Am. Assoc. Cancer Res., 24, 18 (Abstract).
SCHWARTZ, E.L. & WIERNIK, P.H. (1985). Differentiation
of leukemia cells by chemotherapeutic agents. Leuk
Res. (in press).
SKUBITZ, K.M. & AUGUST, J.T. (1983). Analysis of cell-
surface protein changes accompanying differentiation
of HL-60 cells. Arch. Biochem. Biophys., 226, 1.
SOKOLSKI, J.A. & SARTORELLI, A.C. (1984). Induction of
differentiation of HL-60 promyelocytic leukemia cells
by inhibitors of IMP dehydrogenase. Proc. Am. Assoc.
Cancer Res., 25, 42 (Abstract).
STUDZINSKI, G.P. & ELLEM, K.A.O. (1968). Differences
between diploid and heteroploid cultured mammalian
cells in their response to puromycin aminonucleoside.
Cancer Res., 28, 1773.
SUN, T.T. & GREEN, H. (1976). Differentiation of the
epidermal keratinocyte in cell culture: Formation of
the cornified envelope. Cell, 9, 511.
TAETLE, R., HONEYSETT, J.M. & TROWBRIDGE, I.S.
(1983). Effects of anti-transferrin receptor antibodies
on growth of normal and malignant myeloid cells. Int.
J. Cancer, 32, 343.
TAETLE, R., RHYNER, K., CASTAGNOLA, J., TO, D. &
MENDELSOHN, J. (1985). Role of transferrin, Fe, and
transferrin receptors in myeloid leukemia cell growth.
J. Clin. Invest., 75, 1061.
TAKENAGA, K., HOZUMI, M. & SAKAGAMI, Y. (1980).
Effects of retinoids on induction of differentiation of
cultured mouse myeloid leukemia cells. Cancer Res.,
40, 914.
TEI, D., MAKINO, Y., SAKAGAMI, H., KANAMARA, I. &
KONNO, K. (1982). Decrease of transferrin receptor
during mouse myeloid leukemia (M1) cell
differentiation. Biochem. Biophys. Res. Commun., 107,
1419.
TERADA, M., EPNER, E., NUDEL, U. & 4 others. (1978).
Induction of murine erythroleukemia differentiation by
actinomycin D. Proc. Natl Acad. Sci., 75, 2795.
TESTA, U., THOMOPOULOS, P., VINCI, G. & 4 others
(1982). Transferrin binding to K562 cell line. Effect of
heme and sodium butyrate induction. Exp. Cell Res.,
140, 251.
TROWBRIDGE, I.S., LESLEY, J. & SCHULTE, R. (1982).
Murine cell surface transferrin receptor: Studies with
an anti-receptor monoclonal antibody. J. Cell.
Physiol., 112, 403.
TROWBRIDGE, I.S. & LOPEZ, F. (1982). Monoclonal
antibody to transferrin receptor blocks transferrin
binding and inhibits human tumor cell growth in vitro.
Proc. Natl Acad. Sci., 79, 1175.
WARRELL, R.P., ARLIN, Z., GEE, T., LACHER, M. &
YOUNG, C. (1981). Phase I-II evaluation of
aclacinomycin A in acute leukemia. Proc. Am. Assoc.
Cancer Res., 22, 191 (Abstract).
WILLIE, J.J., Jr., PITTLEKOW, M.R., SHIPLEY, G.D. &
SCOTT, R.E. (1984). Integrated control of growth and
differentiation of normal human prokeratinocytes
cultured in serum-free medium: Clonal analyses,
growth kinetics, and cell cycle studies. J. Cell. Physiol.,
121, 31.
WOTRING, L.L. & ROTI ROTI, J.L. (1980). Thioguanine-
induced S and G2 blocks and their significance to the
mechanism ofcytotoxicity. Cancer Res., 40, 1458.
.YAMADA, K., NAKAMURA, T., TSURAO, T. & 14 others
(1980). A phase II study of aclacinomycin A in acute
leukemia in adults. Cancer Treat. Rep., 7, 177.302 A.C. SARTORELLI
YEH, C.G., PAPAMICHAEL, M. & FAULK, W.P. (1982).
Loss of transferrin receptors following induced
differentiation of HL-60 promyelocytic leukemia cells.
Exp. Cell Res., 138, 429.
YEN, A. (1984). Control of HL-60 myeloid differentiation.
Evidence of uncoupled growth and differentiation
control, S-phase specificity, and two-step regulation.
Exp. Cell Res., 156, 198.
YEN, A., REECE, S.A. & ALBRIGHT, K.L. (1984).
Dependence of HL-60 myeloid cell differentiation on
continuous and split retinoic acid exposures:
Precommitment memory associated with altered
nuclear structures. J. Cell. Physiol., 118, 277.
YOUNG, R.C., OZOLS, R.F. & MYERS, C.E. (1981). The
anthracycline antineoplastic drugs. N. Engl. J. Med.,
305, 139.
YUSPA, S.H. & MORGAN, D.L. (1981). Mouse skin cells
resistant to terminal differentiation associated with
initiation ofcarcinogenesis. Nature, 293, 72.